A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection

Background: Bevacizumab is active in the treatment of metastatic colorectal cancer (mCRC). However, efficacy of bevacizumab has predominantly been evaluated on selected patients with relatively good performance status and minor comorbidities. We evaluated the efficacy and safety of bevacizumab in unselected patients with mCRC, some of whom underwent liver resection.

Material and methods: All patients with inoperable mCRC, fit for combination chemotherapy (n = 180), who were initially not resectable, not included into studies and without contraindications to bevacizumab, and initiated on bevacizumab at the Helsinki University Central Hospital between April 2004 and December 2005 were included (n = 114). Most (n = 70) received 5-fluorouracil/leucovorin/irinotecan plus bevacizumab as first-line therapy. The remainder (n = 44) of the patients received bevacizumab in combination with oxaliplatin or irinotecan with or without 5-fluorouracil or capecitabine. Minimum follow-up was 7 years. Treatment response was evaluated every 8–10 weeks according to RECIST criteria.

Results: Median age was 59.6 years (range 35–79); male/female ratio was 54%/46%; World Health Organization performance status 0/1/2–3 was 33%/55%/11%, respectively; and the number of metastatic sites, one/two/three or more, was 31%/21%/48%, respectively. Median duration of bevacizumab therapy was 7.8 months (range 0.5–70.5 with pauses). In first-line (n = 40), response rate (RR) was 62%, progression-free survival (PFS) 11.7 months, and overall survival (OS) 22.1 months. In second-line (n = 43), RR was 44%, PFS 8.7 months, and OS 18.7 months. In later lines (n = 31), RR was 14%, PFS 6.7 months, and OS 14.2 months. Ten patients with initially unresectable liver metastases became operable and R0 resection was achieved in 90% (9/10 resections). In 23% (7/31) of operated metastases, no vital tumor cells were found histologically. Operative morbidity was low: two mild infections, no increased bleeding tendency was noticed, and no impaired wound healing occurred.

Discussion: Bevacizumab-containing combination therapy was effective with acceptable tolerability in an unselected mCRC patient population in which liver resections could be safely performed.

Keywords: everyday clinical practice, colorectal cancer, metastatic, liver resection

Introduction

Colorectal cancer (CRC) remains an urgent health concern, being the second most common cancer worldwide, despite improvements in systemic chemotherapy. For example, in Finland in 2010 there were 2,744 new cases of CRC. Bevacizumab (Avastin®; Genentech/Roche, Basel, Switzerland) is a recombinant humanized monoclonal antibody with selectivity against vascular endothelial growth factor that is approved for use as first- and second-line treatment of metastatic CRC (mCRC). Overall survival benefit in mCRC was found with bevacizumab in three Phase III
studies and one combination analysis of three studies. Benefits with bevacizumab in mCRC have been reported when used in combination with irinotecan/5-fluorouracil (5-FU)/leucovorin (LV) (IFL), 5-FU/LV, capcitabine/oxaliplatin (XELOX), and 5-FU/LV/oxaliplatin (FOLFOX). These findings were supported by survival data from large patient registry and postmarketing surveillance studies carried out in the US and Europe (BRiTE, FirstBEAT and ARIES).

A number of patient- and disease-related factors may need to be considered when evaluating candidates for bevacizumab-related therapy, such as history of recent severe arterial thromboembolic events or venous thrombosis, history of gastrointestinal (GI) perforation, noncontrolled hypertension, and resectability of liver metastases. Data regarding liver resections of cetuximab- and bevacizumab-treated patients were limited in 2004–2005 and, therefore, borderline resectable patients received chemotherapy with FOLFOX. Much of the randomized data on bevacizumab were on relatively young first-line patients with excellent performance status and usually only one metastatic site, which is unlike the clinical situation facing many oncologists.

The aim of this retrospective single-institution analysis was to evaluate the safety and efficacy of bevacizumab treatment and feasibility of liver resection in a cohort of unselected mCRC patients initiating bevacizumab-containing chemotherapy between April 2004 and December 2005.

**Patients and methods**

**Retrospective analysis of the use of bevacizumab in mCRC**

The findings from a retrospective analysis of the use of bevacizumab at the Department of Oncology, Helsinki University Central Hospital (HUCH) (catchment area 1.5 million inhabitants) are reported.

Bevacizumab has been used as a standard treatment in mCRC at HUCH since April 2004. During the inclusion period (April 2004 to December 2005), 825 cases of CRC were diagnosed (Figure 1). Of these 825 patients, 225 were fit for chemotherapy for mCRC, of whom 45 were given single agents (due to age and poor performance status or patient preference) leaving 180 that started combination chemotherapy and were considered for bevacizumab treatment. Further exclusion was due to neoadjuvant chemotherapy for potentially resectable disease (n=20), inclusion into trials (n=16), and contraindications for bevacizumab treatment (n=30; brain metastases, high dose nonsteroidal anti-inflammatory drugs, prior pulmonary embolism, recent venous thromboembolic event, and prior arterial thromboembolic event or baseline proteinuria).

![Figure 1](https://www.dovepress.com/...)
All patients diagnosed with inoperable mCRC and initiating treatment with bevacizumab at HUCH between April 2004 and December 2005 were included in the analysis (n=114). During that time, bevacizumab-containing therapy was not routinely used in patients considered for liver or lung resection. However, ten of these 114 (9%) initially inoperable patients subsequently underwent resection of liver metastases after having been treated with bevacizumab-containing chemotherapy.

The standard first-line therapy for mCRC at HUCH was 5-FU/LV/irinotecan (FOLFIRI) plus bevacizumab; most patients (n=70) received FOLFIRI plus bevacizumab as first-line therapy. In those patients who had not previously received bevacizumab, and when FOLFIRI was considered contraindicated as second- or later-line therapy, bevacizumab was added to irinotecan-, oxaliplatin-, or 5-FU-based therapy, depending on the previous chemotherapy regimen. Irinotecan-based therapy was used in 22 patients (capecitabine/irinotecan, IFL, or single irinotecan), oxaliplatin-based therapy in 12 patients (FOLFOX or XELOX), and 5-FU-based therapy in nine patients (5-FU/LV modified de Gramont regimen or capecitabine). One dihydropyrimidine dehydrogenase-deficient patient received single-agent bevacizumab.

Data from all patients starting bevacizumab therapy between April 2004 and December 2005 were collected. Data cut-off was set at September 4, 2013 for safety and efficacy, which resulted in a minimum follow-up of 7.7 years for the six patients alive; one patient was lost to follow-up. Patient demographics, adverse events, hospitalizations, and treatment efficacy were recorded and collated. All cancer treatments before, during, and after bevacizumab were recorded, including chemotherapy, radiotherapy, and operations. Treatment response was evaluated according to RECIST criteria by whole body spiral computerized tomography (CT) performed every 8–10 weeks. The data monitoring system and procedure was approved by HUCH, Helsinki, Finland were evaluated. Patient baseline demographics are shown in Table 1. Overall, the median age at bevacizumab initiation was 59.6 years (range 35–79); 54% of patients were males and 46% females. The primary tumor site was colon in 56% and rectum in 44% of patients. The baseline metastatic sites, %

### Statistical analyses
All statistical analyses were performed using a StatView statistical package (Berkley, CA, USA) and sigma-plot version 11.0 (Systat Software GmbH, San Jose, CA, USA). Nonnormal distributions were compared with the Mann–Whitney $U$-test. Survival analyses were carried out using the Kaplan–Meier method. Frequency tables were analyzed using the $\chi^2$ test. Progression-free survival (PFS) was defined as the time from the date of initiation of the bevacizumab-containing therapy to the day of documented disease progression or death due to any cause, or was censored at last follow-up. Overall survival (OS) was defined as the time from the date of initiation of bevacizumab-containing therapy to the date of death or was censored at last follow-up. The data were stratified by the line of treatment.

### Results

#### Patient-population evaluated
In total, 114 patients who initiated bevacizumab-containing treatment for mCRC between April 2004 and December 2005 at HUCH, Helsinki, Finland were evaluated. Patient baseline demographics shown in Table 1. Overall, the median age at bevacizumab initiation was 59.6 years (range 35–79); 54% of patients were males and 46% females. The primary tumor site was colon in 56% and rectum in 44% of patients. The baseline metastatic sites, %

#### Table 1 Patient baseline demographics by line of treatment

<table>
<thead>
<tr>
<th>All (n=114)</th>
<th>1st line (n=40)</th>
<th>2nd line (n=43)</th>
<th>3rd to 7th line (n=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years (range)</td>
<td>59.6 (35–79)</td>
<td>62.6 (35–78)</td>
<td>57.2 (35–79)</td>
</tr>
<tr>
<td>Sex, %</td>
<td>Male/female</td>
<td>54/46</td>
<td>43/57</td>
</tr>
<tr>
<td>Primary site, %</td>
<td>Colon</td>
<td>56</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Rectum</td>
<td>44</td>
<td>35</td>
</tr>
<tr>
<td>WHO PS, %</td>
<td>0</td>
<td>33</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>55</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>2–3</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>Number of metastatic sites, %</td>
<td>1</td>
<td>31</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>21</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>3+</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>Liver metastases</td>
<td>Present</td>
<td>72</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>Liver only site</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Resection of primary site, %</td>
<td>No/yes</td>
<td>83/17</td>
<td>85/15</td>
</tr>
</tbody>
</table>

**Abbreviations:** PS, performance status; WHO, World Health Organization.
World Health Organization (WHO) performance status (PS) was 0 in 33%, PS 1 in 55%, and PS 2–3 in 11% of patients. Almost half of the patients (48%) had three or more metastatic sites, and an unresected primary tumor or local recurrence was present in 17% of patients. Details of patients’ previous therapy (radiotherapy, adjuvant therapy, chemotherapy) stratified by the line of treatment are shown in Table 2.

### Treatment duration

The median duration of bevacizumab therapy in the entire cohort of 114 patients was 7.8 months (range 0.5–70.5 with pauses). The median duration of therapy for the 70 patients who received bevacizumab plus FOLFIRI was 8.1 months (range 0–32), and for the 44 patients who received bevacizumab plus other therapy it was 5.5 months (range 0–29). Analysis by line of treatment revealed that the patients who received bevacizumab as first-line treatment (n=40) had a median duration of therapy of 8.3 months (range 0–15) compared with 5.7 (range 0–21) and 6.4 months (range 0–22) for those who received it as second- (n=43) and third-to-seventh-line (n=31), respectively.

### Table 2 Patients’ previous therapy (radiotherapy, adjuvant therapy, chemotherapy) at entry by line of treatment and therapy in further lines of therapy after bevacizumab failure

<table>
<thead>
<tr>
<th>All (n=114)</th>
<th>1st line (n=40)</th>
<th>2nd line (n=43)</th>
<th>3rd to 7th line (n=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>69</td>
<td>80</td>
<td>68</td>
</tr>
<tr>
<td>5×5 Gy</td>
<td>16</td>
<td>15</td>
<td>16</td>
</tr>
<tr>
<td>45–50 Gy</td>
<td>15</td>
<td>5</td>
<td>16</td>
</tr>
<tr>
<td>Adjuvant therapy, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>71</td>
<td>75</td>
<td>70</td>
</tr>
<tr>
<td>5-FU-based</td>
<td>26</td>
<td>25</td>
<td>21</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>4</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Pre-bevacizumab chemotherapy, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>35</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>5-FU-based</td>
<td>65</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>35</td>
<td>0</td>
<td>28</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>46</td>
<td>0</td>
<td>58</td>
</tr>
<tr>
<td>Other¹</td>
<td>8</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Post-bevacizumab chemotherapy, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>30</td>
<td>25</td>
<td>26</td>
</tr>
<tr>
<td>5-FU-based</td>
<td>48</td>
<td>50</td>
<td>56</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>20</td>
<td>15</td>
<td>26</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>25</td>
<td>38</td>
<td>21</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>18</td>
<td>13</td>
<td>21</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>17</td>
<td>25</td>
<td>14</td>
</tr>
<tr>
<td>Other¹</td>
<td>4</td>
<td>5</td>
<td>2</td>
</tr>
</tbody>
</table>

**Note:** ¹Other chemotherapy included raltitrexed, gemcitabine, mitomycin C, taxanes, PTK787, and erlotinib.

**Abbreviations:** 5-FU, 5-fluorouracil; Gy, Gray.

### Clinical efficacy of bevacizumab in mCRC

In all 114 patients, the response rate (RR) was 42% and the disease control rate was 89%. The median PFS was 8.8 months and the median OS was 18.4 months.

In first-line patients (n=40), RR was 62% and the median PFS 11.7 months and three patients (8%) were in remission at the minimum of 7.7 years (Figure 2). Median OS time for the first-line patients was 22.1 months, and 13% of patients were still alive at the minimum of 7.7 years (data cut-off, September 4, 2013) (Figure 3). In second-line patients (n=43), RR was 44% and the median PFS was 8.2 months (Figure 2). The median OS in second-line therapy was 18.7 months and one patient (2%) was alive at data cut-off (Figure 3). In third- to seventh-line patients (n=31), RR was 14%, PFS was 6.7 months (Figure 2), and OS was 14.2 months (Figure 3).

Evaluation of the best response to treatment in the overall population and by line of treatment revealed that the RR was higher among patients who received bevacizumab as part of first-line therapy versus second- or later-line therapies (P=0.012 for first- versus second- versus third-line therapy; Table 3). For both PFS and OS, there was a significant trend of bevacizumab being more effective when given early (ie, as first-line rather than as second- or later-line treatment; PFS P=0.037 and OS P<0.001).

Further chemotherapy after progression on bevacizumab was given to 70% of patients (Table 2). All of the three most important chemotherapeutic agents for colorectal cancer patients by line of treatment.

![Figure 2 Progression-free survival with chemotherapy involving bevacizumab in CRC patients by line of treatment.](https://www.dovepress.com/)

**Abbreviation:** CRC, colorectal cancer.
adenocarcinoma (5-FU, oxaliplatin, and irinotecan) were used at some phase in the treatment in 69% of the patients. Cetuximab was given to 18% of the patients and their median OS was 39.7 months. Bevacizumab beyond progression was given to 17% of patients with a median OS of 32.7 months. Seven patients (6%) responded to first line “stop-and-go” irinotecan, 5-FU, and bevacizumab therapy for more than 5 years (median 6.4 years, range 5.5–8.0).

Clinical safety of bevacizumab in mCRC
The safety profile with bevacizumab was as anticipated with adverse events and their severity being as predicted. There were no treatment-related deaths. The majority of bevacizumab-related adverse events were bleeding/ulceration, arterial thromboembolic events, and perforation, with most of these being no more than grade 2 in severity (Table 4). The majority of adverse events reported during combination chemotherapy were likely due to the cytotoxic chemotherapy partner.

Serious adverse events were as predicted with no difference between lines of treatment in the proportion of patients requiring hospitalization for any reason (all patients: 39% had in-hospitalizations; first-line: 18 patients [45%]; second-line: 15 patients [35%]; third-line: 12 patients [39%]). Chemotherapy-related toxicity led to hospitalizations in 41 patients (36%) and bevacizumab-related events (GI perforation, arterial thromboembolic event, or rectal bleed) in eleven patients (10%). The remainder (seven patients, 6%) were hospitalized due to constitutional symptoms caused by disease progression or due to elective surgery.

Use of bevacizumab in initially unresectable liver metastases prior to liver resection
In 2004, no data regarding liver resection of bevacizumab-treated patients were available, and potentially resectable patients were given neoadjuvant FOLFOX chemotherapy. Only patients with nonresectable disease and high tumor burden initiated bevacizumab-containing therapy. Only 20% of patients had liver-only disease (Table 1). Ten out of 114 patients (9%) who had started chemotherapy combined with bevacizumab in 2004–2005 with initially nonresectable liver metastases subsequently underwent liver resection.

These 10 patients had a total of 66 metastases, visualized by radiological examinations prior to initiation of bevacizumab and chemotherapy. Upon CT-scan within 4 weeks prior to resection, only 35 (53%) of these lesions could be found. In the operating theatre, 32 of the 66 (48%)}
metastases were identified by palpation and peroperative ultrasound. Of these, 31 were resected and one was destroyed with radiofrequency ablation. The median number of removed metastases per patient was three (range one to six) and the median size of the biggest lesion was 1.9 cm (range 0.4–6.0). R0 resections were achieved in 90% (nine out of ten) of operations, and 23% (seven out of 31) of lesions did not contain vital tumor cells in rigorous histological examination.

Bevacizumab was interrupted for a median of 47 days (range 36–196) before surgery and restarted a median of 30 days (range 27–60) after resection. Median in-hospitalization time was 8 days (range 7–14). Morbidity was low: bleeding was limited with median perioperative erythrocyte transfusion of 1 unit (range 0–6); two mild infections were noted; and wound healing was not impaired. Two patients experienced reversible atrial fibrillation postoperatively. Three months after resection, liver regeneration had occurred as anticipated; liver synthesizing capacity, liver enzymes, and CT control were back to baseline (Table 5).

Re-resections have been performed in three patients. Altogether, 13 liver resections have been performed in these patients. The re-resections were performed 9–14 months after the previous resection. All four re-resections were performed safely and the postoperative course has been as anticipated. One of the ten patients who underwent liver resection is presented in Figure 4.

| Table 5 | Key laboratory findings in ten patients at first liver resections preoperatively, at discharge after liver resection, and at 3 months postoperatively |
|-----------------|-----------------|-----------------|-----------------|
| Liver tests (reference range) | Preoperative | At discharge | 3 months postoperatively |
| ALT, U/L | 13 (10–19) | 63 (51–132) | 22 (18–23) |
| AFOS, U/L | 74 (52–155) | 145 (76–173) | 118 (75–188) |
| Total bilirubin, μmol/L | 10 (9–12) | 10 (9–10) | 11 (9–13) |
| TT-SPA, % | 110 (98–130) | 57 (51–73) | 106 (98–110) |
| Galactose elimination, T1/2 (minutes) | 12.8 (11.7–16.6) | 19.5 (15.9–23.5) | Not done |
| Albumin, mg/L | 40.3 (37–41) | 34.8 (31–36) | 36.6 (35–40) |
| Prealbumin, mg/L | 261 (222–276) | 120 (100–142) | 243 (209–281) |
| Cholesterol, mmol/L | 5.0 (4.4–6.0) | 3.1 (2.8–3.3) | 4.9 (4.8–5.2) |
| CEA, kU/L | 3.5 (1.7–4.7) | 1.8 (1.2–3.6) | 2.5 (1.2–5.7) |
| Ca 19-9, kU/L | 7 (1–12) | 12 (9–20) | 6 (4–9) |

Note: Data are presented as median with interquartile range. 
Abbreviations: ALT, alanine aminotransferase; AFOS, alkaline phosphatase; Ca 19-9, Cancer Antigen 19-9; CEA, carcinoembryonic antigen; TT-SPA, thromboplastin time; T1/2, half-life.

Median survival for the ten out of 114 resected patients was 23.2 months (interquartile range 18–69 months) and 18.4 months for the 94 non-resected patients (interquartile range 11–31, P=0.09).

**Discussion**

This single-institution analysis demonstrates that the safety and efficacy of bevacizumab in the everyday clinical practice setting (ie, a cohort of unselected mCRC patients) is in line with randomized trials. Focusing on the safety profile of bevacizumab, there were no treatment-related deaths, and bevacizumab-related adverse events were as anticipated (bleeding/ulceration, arterial thromboembolic events, and GI perforation), with most being not more than grade 2 in severity. These adverse effects were manageable in everyday practice.

The PFS and OS found in this study in patients who received bevacizumab as part of first-line therapy (11.7 and 22.1 months, respectively) is in line with data reported from the BRiTE registry (PFS 10.1 months; OS 27.1 months) and

![Figure 4](https://example.com/figure4.png)

**Figure 4** A 42 year old female patient with lung metastases and four synchronous liver metastases.

**Notes:** A rectal cT4N2M1 disease was diagnosed in October 2004 (A). After 14 months of FOLFIRI plus bevacizumab chemotherapy and chemoradiation, radiologic complete response was noted in lung metastases and the patient underwent anterior resection in August 2006 with a pathologic complete response in histology. Liver resection was performed in October 2006 and CT findings preoperatively showed four metastases (B). In histology, no vital tumor cells were found in the resected liver tissue, including all four metastases. In 7 year follow-up, no signs of recurrence in liver or lung have been noted. One FDG-negative lesion was seen prior to resection on PET/CT scan (C).

**Abbreviations:** CT, computerized tomography; FOLFIRI, 5-fluorouracil/leucovorin/irinotecan; pCR, pathologic complete response; PET, positron emission tomography; FDG, fluoro-deoxyglucose.
the FirstBEAT trial (PFS 10.8 months; OS 22.7 months). However, in contrast to these two studies, the patients reported on here had a higher tumor burden (48% of patients with three or more metastatic sites) and 55% had WHO PS of 1 (and 11% WHO PS 2–3), compared with 42% and 34% of patients with a PS of 1 in the other two trials. Interestingly, the safety profiles of bevacizumab reported here and in the FirstBEAT study were similar, with the major grade 3/4 bevacizumab-related adverse events of bleeding/ulceration, GI perforation, and arterial thromboembolic events all reported with a difference in frequency of less than 1.5% between the studies.

The clinical efficacy of bevacizumab-containing regimens in first-line mCRC varied relatively little with the chemotherapy backbone used. These findings are supported by randomized clinical trials where bevacizumab was used in combination with 5-FU/LV, IFL, FOLFIRI, FOLFOX, XELOX, and bevacizumab-containing chemotherapy backbone used. These findings are supported by randomized clinical trials where bevacizumab was used in combination with 5-FU/LV, IFL, FOLFIRI, FOLFOX, XELOX, and bevacizumab-containing chemotherapy backbone used. These findings are supported by randomized clinical trials where bevacizumab was used in combination with 5-FU/LV, IFL, FOLFIRI, FOLFOX, XELOX, and bevacizumab-containing chemotherapy backbone used.

In conclusion, these efficacy and tolerability findings relating to bevacizumab-containing combination therapy administered to an unselected patient population are in line with the results of randomized studies in mCRC. Treatment-related toxicity was acceptable. Furthermore, liver resections may be performed safely among patients treated with bevacizumab.

**Disclosure**

Pia Osterlund has received honoraria for advisory boards, lecturing, consulting, and travel grants from Amgen, Bayer, Celgene, Lilly, Merck, Roche, and Sanofi, and research funding from Amgen, Roche, and Sanofi. Tuomo Alanko has received honoraria for advisory board membership, lecturing, consulting, and travel grants from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Lilly, and other companies.
Pfizer, Pierre Fabre, Roche, and Sanofi. Petri Bono has had a role in Advisory Boards or given an expert testimony for GlaxoSmithKline, Pfizer, and Novartis. Helena Isoniemi has received honoraria for advisory board membership, lecturing and travel grants from Roche. Editorial assistance was provided by Miller Medical Communications Ltd, funded by Roche, Finland. Reetta Peltonen reports no conflicts of interest in this work.

References


